P-TEV
Phase 1- Indications
- Chronic venous insufficiency
Company intelligence / Profile preview
VERIGRAFT
Gothenburg, Swedenverigraft.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Phase 1
01
Overview
VERIGRAFT has developed a proprietary technology that transforms donated allogeneic tissues into personalized grafts resembling the patient’s own tissue. This approach aims to eliminate transplant rejection and the need for lifelong immunosuppression. The company’s pipeline includes vascular grafts and peripheral nerve repair products in preclinical or early clinical stages.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Tissue-engineered grafts (personalized veins, arteries, nerves, heart valves)Decellularization and recellularization of allogeneic tissue
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on VERIGRAFT.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERIGRAFT.